Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 2/20 | 0.42 |
| ▸ | GSK3A | P49840 | 2/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | HINT1 | P49773 | 3/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.35 |
| ▸ | KRAS | P01116 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16870623 | 0.92 | PNP (0.44) | PNPGSK3ARPS6KA3MAPK14HINT1 | |
| SCHEMBL18475039 | 0.80 | PNP (0.45) | PNPGSK3ARPS6KA3MAPK14HINT1 | |
| SCHEMBL16214945 | 0.79 | POLB (0.37) | NT5E | |
| SCHEMBL18475067 | 0.79 | PNP (0.44) | PNPGSK3ARPS6KA3MAPK14HINT1 | |
| SCHEMBL18477849 | 0.79 | PNP (0.44) | PNPGSK3ARPS6KA3MAPK14HINT1 | |
| SCHEMBL20250997 | 0.77 | TAAR1 (0.45) | PNPGSK3ARPS6KA3MAPK14HINT1 | |
| SCHEMBL16214171 | 0.77 | ADORA3 (0.47) | PNPHINT1HPRT1ADORA3NT5E | |
| SCHEMBL16866666 | 0.77 | ADORA3 (0.42) | PNPHINT1TAAR1HPRT1ADORA3 | |
| SCHEMBL16214934 | 0.76 | POLB (0.47) | NT5E | |
| SCHEMBL16214109 | 0.76 | ADORA3 (0.39) | PNPHINT1XDHHPRT1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264610-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-9346848-B2 | Azido nucleosides and nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150183819-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2015-07-02 | — | — | US | disclosed |
| US-8877731-B2 | Azido nucleosides and nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20120070415-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264610-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | PNP, ADA, ADAR | PNP 1/4885GSK3A 1512/4885RPS6KA3 3590/4885 |
| US-20120070415-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | PNP, ADA, ADAR | PNP 1/4885GSK3A 1512/4885RPS6KA3 3590/4885 |
| US-20150183819-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | PNP, ADA, ADAR | PNP 1/4885GSK3A 1512/4885RPS6KA3 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.